DALLAS, Dec. 06, 2023 (GLOBE NEWSWIRE) -- AMN Healthcare Services, Inc. (NYSE: AMN), the leader and innovator in total talent solutions for healthcare organizations across the United States, has been recognized as one of America’s Most Responsible Companies for 2024. This recognition is a tribute to AMN Healthcare’s excellence in corporate citizenship and commitment to Environment, Social and Corporate Governance (ESG). This prestigious award is presented by Newsweek and Statista Inc., the world-leading statistics portal and industry ranking provider. America’s Most Responsible Companies ranking focuses on a holistic view of corporate responsibility that considers all three pillars of ESG and is based on two metrics:
In the final step, an overall score was calculated for each company that had been analyzed. The final list recognizes the top 600 most responsible companies in the United States, spanning 14 industries.
"We are proud to be recognized, for the fifth consecutive year, for our commitment to a healthy, just, equitable, and sustainable world where all can thrive," said Cary Grace, President and CEO of AMN Healthcare. "AMN Healthcare embraces this commitment and will continue our dedication to creating sustainable and equitable outcomes as we empower the future of care and the health of our communities."
About Statista
Statista publishes hundreds of worldwide industry rankings and company listings with high profile media partners. This research and analysis service is based on the success of statista.com, the leading data and business intelligence portal that provides statistics, business-relevant data, and various market and consumer studies and surveys.
About AMN Healthcare
AMN Healthcare is the leader and innovator in total talent solutions for healthcare organizations across the United States. The Company provides access to the most comprehensive network of quality healthcare professionals through its innovative recruitment strategies and breadth of career opportunities. With insights and expertise, AMN Healthcare helps providers optimize their workforce to successfully reduce complexity, increase efficiency and improve patient outcomes. AMN total talent solutions include managed services programs, clinical and interim healthcare leaders, temporary staffing, permanent placement, executive search solutions, vendor management systems, recruitment process outsourcing, predictive modeling, language interpretation services, revenue cycle solutions, and other services. Clients include acute-care hospitals, community health centers and clinics, physician practice groups, retail and urgent care centers, home health facilities, schools, and many other healthcare settings. AMN Healthcare is committed to fostering and maintaining a diverse team that reflects the communities we serve. Our commitment to the inclusion of many different backgrounds, experiences and perspectives enables our innovation and leadership in the healthcare services industry. For more information about AMN Healthcare, visit www.amnhealthcare.com.
Media Contact Corporate Communications AMN Healthcare This email address is being protected from spambots. You need JavaScript enabled to view it. | Investor Contact Randle Reece Senior Director, Investor Relations & Strategy AMN Healthcare (866) 861-3229 This email address is being protected from spambots. You need JavaScript enabled to view it. |
Last Trade: | US$27.79 |
Daily Change: | 0.96 3.58 |
Daily Volume: | 488,470 |
Market Cap: | US$1.060B |
November 07, 2024 August 27, 2024 August 08, 2024 July 09, 2024 May 09, 2024 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load